BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A. The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses 2020;12:E746. [PMID: 32664401 DOI: 10.3390/v12070746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Ning J, Cao W, Wang S, Du T, Jiang J, Feng X, Zhang B. Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers. Front Oncol 2020;10:568574. [PMID: 33194655 DOI: 10.3389/fonc.2020.568574] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Ma H, Hei A, Zhou J, He E, Skog S, Li J. Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis. Future Sci OA 2021;7:FSO717. [PMID: 34258026 DOI: 10.2144/fsoa-2021-0016] [Reference Citation Analysis]
3 Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J, Kramvis A. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol 2021;12:661204. [PMID: 33995383 DOI: 10.3389/fimmu.2021.661204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Asín-Prieto E, Parra-Guillen ZP, Gómez Mantilla JD, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. A quantitative systems pharmacology model for acute viral hepatitis B. Comput Struct Biotechnol J 2021;19:4997-5007. [PMID: 34589180 DOI: 10.1016/j.csbj.2021.08.052] [Reference Citation Analysis]
5 Zhao P, Lu Y, Wang C, Wang L, Li J, Li M. Clinical, Pathological and Genetic Characteristics of Pediatric Hepatocellular Carcinoma Associated with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:361-7. [PMID: 34007834 DOI: 10.2147/JHC.S306963] [Reference Citation Analysis]
6 Loureiro D, Tout I, Narguet S, Benazzouz SM, Mansouri A, Asselah T. miRNAs as Potential Biomarkers for Viral Hepatitis B and C. Viruses 2020;12:E1440. [PMID: 33327640 DOI: 10.3390/v12121440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Reference Citation Analysis]
8 Zhuang H, Ma X, Liu X, Li C, Li X, Wu L, Wen M, Shi W, Yang X. Hyaluronan-mediated motility receptor antisense RNA 1 promotes hepatitis B virus-related hepatocellular carcinoma progression by regulating miR-627-3p/High Mobility Group AT-hook 2 axis. Bioengineered 2022;13:8617-30. [PMID: 35322735 DOI: 10.1080/21655979.2022.2054151] [Reference Citation Analysis]
9 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Reference Citation Analysis]
10 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
11 Zhang C, Wang Q, Liu AQ, Zhang C, Liu LH, Lu LF, Tu J, Zhang YA. MicroRNA miR-155 inhibits cyprinid herpesvirus 3 replication via regulating AMPK-MAVS-IFN axis. Dev Comp Immunol 2021;129:104335. [PMID: 34929233 DOI: 10.1016/j.dci.2021.104335] [Reference Citation Analysis]